PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
Authors
Keywords
Poorly differentiated thyroid carcinoma, PD-L1, IDO1, PD1, Programmed cell death ligand 1, Indoleamine 2,3-dioxygenase 1, Immune checkpoint, Immuno-oncology
Journal
ENDOCRINE PATHOLOGY
Volume 29, Issue 1, Pages 59-67
Publisher
Springer Nature
Online
2018-01-25
DOI
10.1007/s12022-018-9514-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive screening for PD-L1 expression in thyroid cancer
- (2017) Soomin Ahn et al. ENDOCRINE-RELATED CANCER
- Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
- (2017) Panagiotis Balermpas et al. INTERNATIONAL JOURNAL OF CANCER
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
- (2017) Revathi Kollipara et al. ONCOLOGIST
- Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence
- (2017) Rong-liang Shi et al. THYROID
- Lenvatinib: Role in thyroid cancer and other solid tumors
- (2016) Maria E. Cabanillas et al. CANCER TREATMENT REVIEWS
- Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma
- (2016) Bin Xu et al. ENDOCRINE PATHOLOGY
- TERTpromoter mutations in thyroid cancer
- (2016) Rengyun Liu et al. ENDOCRINE-RELATED CANCER
- Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1
- (2016) Sonia Moretti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
- (2016) Iñigo Landa et al. JOURNAL OF CLINICAL INVESTIGATION
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
- (2016) Eran Brauner et al. Oncotarget
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
- (2016) Subrata Chowdhury et al. Oncotarget
- Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer
- (2016) Josephine F. Trott et al. Oncotarget
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
- (2015) John W. Kunstman et al. HUMAN MOLECULAR GENETICS
- PD-L1 Inhibition With MPDL3280A for Solid Tumors
- (2015) Edward Cha et al. SEMINARS IN ONCOLOGY
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
- (2015) J. J. Severson et al. Cancer Immunology Research
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- Poorly differentiated thyroid cancer
- (2014) Kepal N. Patel et al. Current Opinion in Otolaryngology & Head and Neck Surgery
- Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives
- (2014) H. Mirghani et al. INTERNATIONAL JOURNAL OF CANCER
- Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
- (2014) Sonia Moretti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
- (2014) Trevor E. Angell et al. THYROID
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) F. Pacini et al. ANNALS OF ONCOLOGY
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation
- (2012) Lucas Leite Cunha et al. ENDOCRINE-RELATED CANCER
- Programmed Death-1+T Cells and Regulatory T Cells Are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Features in Papillary Thyroid Cancer
- (2012) Jena D. French et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poorly Differentiated Thyroid Carcinomas
- (2011) Matthias Dettmer et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Classification of follicular cell tumors of the thyroid gland: Analysis involving Japanese patients from one institute
- (2009) Kennichi Kakudo et al. PATHOLOGY INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started